Assen Goudev

5.0k citations

37 papers · 408 · 1 hit paper · h-index 9

Impact in

Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 10%
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research

Papers in

Cardiology and Cardiovascular Medicine 29
- Atrial Fibrillation Management and Outcomes 10
- Cardiovascular Function and Risk Factors 9
- Heart Failure Treatment and Management 6
- Antiplatelet Therapy and Cardiovascular Diseases 5
- Blood Pressure and Hypertension Studies 4
- Cardiac Arrhythmias and Treatments 3
Surgery 8
- Cardiac Structural Anomalies and Repair 3

Co-authors: Marc S. Sabatine (6 shared papers)Deepak L. Bhatt (6 shared papers)Sabina A. Murphy (4 shared papers)Eugene Braunwald (5 shared papers)KyungAh Im (4 shared papers)Philippe Gabríel Steg (4 shared papers)Alexander Parkhomenko (4 shared papers)Robert F. Storey (4 shared papers)
Journals: European Heart Journal (5 papers)Cardiology (3 papers)Journal of the American College of Cardiology (3 papers)Circulation (2 papers)European Journal of Heart Failure (2 papers)
Partner nations: Bulgaria United States United Kingdom

In The Last Decade

Assen Goudev

34 papers receiving 396 citations

Hit Papers

align trajectories log scale

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial 2024 · 100 citations

Peers

Countries citing papers authored by Assen Goudev

Since Specialization

Citations

This map shows the geographic impact of Assen Goudev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Assen Goudev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Assen Goudev more than expected).

Fields of papers citing papers by Assen Goudev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Assen Goudev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Assen Goudev. The network helps show where Assen Goudev may publish in the future.

Co-authors

The 25 scholars most cited alongside Assen Goudev, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Assen Goudev Line = papers co-authored together Assen Goudev links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial The Lancet ·John Deanfield, Subodh Verma, Benjamin M. Scirica, Steven E. Kahn, Scott S. Emerson, Donna H. Ryan, Ildiko Lingvay, Helen M. Colhoun, Jorge Plutzky, Mikhail Kosiborod, G Kees Hovingh, Søren Hardt‐Lindberg, Ofir Frenkel, Peter Weeke, Søren Rasmussen, Assen Goudev, Chim C. Lang, Miguel Urina‐Triana, Mikko Pietilä, A. Michael Lincoff, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown) Hit paper breakdown →	2024	100
2	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54 Journal of the American College of Cardiology ·Marc P. Bonaca, Robert F. Storey, Pierre Théroux, Philippe Gabríel Steg, Deepak L. Bhatt, Marc Cohen, KyungAh Im, Sabina A. Murphy, Giulia Magnani, Ton Oude Ophuis, Mikhail Rudah, Alexander Parkhomenko, Daniel Isaza, Gabriel Kamenský, Assen Goudev, Gilles Montalescot, Eva C. Jensen, Per Johanson, Eugene Braunwald, Marc S. Sabatine	2017	52
3	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial European Heart Journal ·Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Kyong Soo Park, Assen Goudev, Rafael Díaz, Jindřich Špinar, Ingrid Gause‐Nilsson, Ofri Mosenzon, Marc S. Sabatine, Stephen D. Wiviott	2021	49
4	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease Journal of the American College of Cardiology ·Sameer Bansilal, Marc P. Bonaca, Jan H. Cornel, Robert F. Storey, Deepak L. Bhatt, Philippe Gabríel Steg, KyungAh Im, Sabina A. Murphy, Dominick J. Angiolillo, Róbert Gábor Kiss, Alexander Parkhomenko, José López‐Sendón, Daniel Isaza, Assen Goudev, Frederic Kontny, Peter Held, Eva C. Jensen, Eugene Braunwald, Marc S. Sabatine, A.J. Oude Ophuis	2018	43
5	Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction European Journal of Heart Failure ·Lars H. Lund, Carolyn S.P. Lam, Patricia Ely Pizzato, Anders Gabrielsen, Erik Michaëlsson, Karin Nelander, Hans Ericsson, Julie Holden, Folke Folkvaljon, Andrea Mattsson, Anna Collén, Malin Aurell, Carl Whatling, Stephan Baldus, Grzegorz Drelich, Assen Goudev, Béla Merkely, Niklas Bergh, Sanjiv J. Shah	2023	22
6	Reduced Concentrations of Soluble Adhesion Molecules after Antioxidant Supplementation in Postmenopausal Women with High Cardiovascular Risk Profiles – A Randomized Double-Blind Study Cardiology ·Assen Goudev, Stanimir Kyurkchiev, V. Gergova, E. Karshelova, Dimiter B. Georgiev, Dan Atar, Ivan Kehayov, C Nachev	2000	21
7	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial International Journal of Cardiology ·Anna Plitt, Christian T. Ruff, Assen Goudev, João Morais, Miodrag Ostojić, Michael Grosso, Hans Lanz, Jeong‐Gun Park, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano	2020	20
8	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction Journal of the American Heart Association ·Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F. Storey, Philippe Gabríel Steg, Deepak L. Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamenský, Dominick J. Angiolillo, José López‐Sendón, Per Johanson, Eugene Braunwald, Marc S. Sabatine, Marc P. Bonaca	2021	17
9	Global longitudinal strain as a marker for systolic function in patients with pheochromocytomas Endocrine Related Cancer ·Атанаска Еленкова, Rabhat Shabani, Elena Kinova, В. Н. Васильев, Assen Goudev, Sabina Zacharieva	2020	8
10	Cardiac myosin‐binding protein C in the diagnosis and risk stratification of acute heart failure European Journal of Heart Failure ·Nikola Kozhuharov, Desirée Wussler, Thomas E Kaier, Ivo Strebel, Samyut Shrestha, Dayana Flores, Albina Nowak, Zaid Sabti, Thomas Nestelberger, Tobias Zimmermann, Joan Walter, Maria Belkin, Eleni Michou, Pedro López‐Ayala, Danielle Menosi Gualandro, Dagmar I. Keller, Assen Goudev, Tobias Breidthardt, Christian Mueller, Michael Marber, (unknown)	2021	7
11	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial European Heart Journal ·Scott D. Solomon, Brian Claggett, Zi Michael Miao, Rafael Díaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Ramón Corbalán, Gerasimos Filippatos, Assen Goudev, Mareev VIu, Pranas Šerpytis, Thomas Suter, Mehmet Birhan Yılmaz, Faı̈ez Zannad, Stuart Kupfer, Stephen B. Heitner, Fady I. Malik, John R. Teerlink	2022	7
12	Serum level of IgG autoantibodies against oxidized low density lipoproteins and lag-phase of serum oxidation in coronary heart disease--inverse correlation. PubMed ·Rumiana Bakalova, Zh. Zhelev, Assen Goudev, St. Ribarov, C Nachev	1999	7
13	Design and methodology of POWER, an open‐label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension Fundamental and Clinical Pharmacology ·Guy De Backer, Robert J. Petrella, Assen Goudev, Ghazi Radaideh, Andrzej Rynkiewicz, Atul Pathak	2011	6
14	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study) The American Journal of Cardiology ·Gregory Y.H. Lip, José Luís Merino, Gheorghe‐Andrei Dan, Sakis Themistoclakis, Kenneth A. Ellenbogen, Raffaele De Caterina, Assen Goudev, James Jin, Michael Melino, Shannon M. Winters, Andreas Goette	2017	5
15	Effect of a Strategy of Comprehensive Vasodilation Versus Usual Care on Health-Related Quality of Life Among Patients with Acute Heart Failure ESC Heart Failure ·Maria Belkin, Desirée Wussler, Danielle Menosi Gualandro, Samyut Shrestha, Ivo Strebel, Assen Goudev, Micha T. Maeder, Joan Walter, Gloria Dayana Flores Díaz, Nikola Kozhuharov, Pedro López‐Ayala, Isabelle Danier, Múcio Tavares de Oliveira, Richard Kobza, Hans Rickli, Tobias Breidthardt, Paul Erné, Thomas Münzel, Christian Mueller	2021	5
16	Effect of Lactobacillus plantarum supplementation on trimethylamine-N-oxide levels in 30 patients with atherosclerotic cardiovascular disease: A double-blind randomized controlled trial SHILAP Revista de lepidopterología ·Natalia Spasova, Desislava Somleva, Bozhidar Krastev, Rositsa Tropcheva, Dobrin Svinarov, Todor Kundurzhiev, Elena Kinova, Assen Goudev	2024	4
17	Torsion Mechanics as an Indicator of More Advanced Left Ventricular Systolic Dysfunction in Secondary Mitral Regurgitation in Patients with Dilated Cardiomyopathy: A 2D Speckle-Tracking Analysis Cardiology ·Elena Kinova, Natalia Spasova, Angelina Borizanova, Assen Goudev	2018	4
18	Abstract 16551: Efficacy and Safety of Oral Anticoagulation in 21105 Patients With Atrial Fibrillation Stratified by Diabetic Status in the ENGAGE AF-TIMI 48 Trial Circulation ·Anna Plitt, Christian T. Ruff, Assen Goudev, João Morais, Jeong‐Gun Park, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano	2016	3
19	EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL Journal of the American College of Cardiology ·Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Kyong Soo Park, Assen Goudev, Rafael Díaz, Jindřich Špinar, Ingrid Gause‐Nilsson, Ofri Mosenzon, Marc S. Sabatine, Stephen D. Wiviott	2020	3
20	Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey International Journal of Hypertension ·Guy De Backer, Robert J. Petrella, Assen Goudev, Ghazi Radaideh, Andrzej Rynkiewicz, Atul Pathak	2013	3

About Assen Goudev

Assen Goudev is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Economics and Econometrics, having authored 37 papers that have together received 408 indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (10 papers), Cardiovascular Function and Risk Factors (9 papers), Heart Failure Treatment and Management (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Diabetes Treatment and Management (4 papers), Blood Pressure and Hypertension Studies (4 papers), Cardiac Arrhythmias and Treatments (3 papers) and Cardiac Structural Anomalies and Repair (3 papers). The work is most often cited by research in Internal Medicine (51 citations), Cardiology and Cardiovascular Medicine (260 citations), Endocrinology, Diabetes and Metabolism (127 citations), Surgery (110 citations) and Pharmacology (36 citations). Assen Goudev has collaborated with scholars based in Bulgaria, United States and United Kingdom. Frequent co-authors include Marc S. Sabatine, Deepak L. Bhatt, Sabina A. Murphy, Eugene Braunwald, KyungAh Im, Philippe Gabríel Steg, Alexander Parkhomenko, Robert F. Storey, Marc P. Bonaca and Elena Kinova. Their work appears in journals such as European Heart Journal, Cardiology, Journal of the American College of Cardiology, Circulation and European Journal of Heart Failure.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Assen Goudev

Impact in

Papers in i

In The Last Decade

Assen Goudev

Hit Papers

Peers

Countries citing papers authored by Assen Goudev

Fields of papers citing papers by Assen Goudev

All Works

About Assen Goudev

Explore authors with similar magnitude of impact

Papers in